Company intelligence / Profile preview

SolasCure

Cambridge, Cambridgeshire, United Kingdomsolascure.com ↗

Ownership: Private
Development stage: Phase 2

Overview

SolasCure recently completed its CLEANVLU proof-of-concept first-in-man Phase IIa safety study examining the use of Aurase Wound Gel in chronic venous leg ulcer subjects. Results are being analyzed. The company enrolled its first patient in a next Phase II clinical trial in March 2025[2][4].

Therapeutic areas: CardiovascularDermatology
Modalities: Enzymatic hydrogel
Industry: Biotech

Drug pipeline

1 asset

aurase

Partnerships

US Army Institute of Surgical Research (USAISR)[6]

Beyond the preview

Go deeper on SolasCure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SolasCure.

Explore the full profile